Clinical Trial Update: Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating azacitidine, venetoclax, and flumatinib in newly diagnosed Ph-positive acute leukemia and CML-AP/BP; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Mixed Phenotype Acute Leukemia
• Philadelphia Chromosome Positive Acute Leukemia

Drugs mentioned

• Flumatinib (flumatinib)
• VIDAZA (AZACITIDINE)
• Venclexta (venetoclax)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Philadelphia Chromosome, Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED